Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

Current Drug Safety

Volumn 6, Issue 1, 2011, Pages 43-45

  Alphs, Larry ^a   Gopal, Srihari ^b   Karcher, Keith ^b   Kent, Justine ^b   Sliwa, Jennifer Kern ^a   Kushner, Stuart ^b   Nuamah, Isaac ^b   Singh, Jaskaran ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Paliperidone palmitate; Post injection delirium sedation syndrome; Risperidone

Indexed keywords

PALIPERIDONE; PLACEBO; RISPERIDONE;

ARTICLE; CATAPLEXY; COMA; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DELIRIUM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; GAIT DISORDER; HUMAN; HYPERSOMNIA; HYPOTENSION; LETHARGY; ORTHOSTATIC HYPOTENSION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; STUPOR; TORSADE DES POINTES; TREATMENT OUTCOME;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; CONSCIOUS SEDATION; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DELIRIUM; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; PALMITATES; PROSPECTIVE STUDIES; RISPERIDONE; SYNDROME;

EID: 79551645374     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611794480070     Document Type: Article

References (11)

1. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006; 67(Suppl 5): 15-18.
2. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a secondgeneration antipsychotic. Int J Clin Pract 2009; 63(1): 140-50.
3. Eli Lilly and Company. Zyprexa olanzapine pamoate (OP) depot. psychopharmacological drugs advisory committee briefing document, 3 January 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf [Accessed: January 2009].
4. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010; 167: 181-9.
5. Gulliver A, McDonnell DP, Sorsaburu S, et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008; 11(Suppl 1): 152.
6. McDonnell DP, Andersen SW, Detke HC, Watson SB. 60-week interim results from an open-label extension trial of olanzapine long-acting injection [poster]. US Psychiatric and Mental Health Congress (USPMHC); San Diego, CA; October 30-November 2, 2008.
7. McDonnell DP, Sorsaburu S, Brunner E, et al. Injection-related adverse events observed with olanzapine long-acting injection [poster]. US Psychiatric and Mental Health Congress (USPMHC); San Diego, CA; October 30-November 2, 2008.
8. Eli Lilly and Company. Important safety information on postinjection delirium/sedation syndrome. February 3, 2010. Available at: http://www.zyrexalprevv.com/index.jsp.55824letter. Accessed: May 14, 2010.
9. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs 2005; 6(3): 129-137.
10. Ramstack J, Grandolfi G, D'Hoore P, Mannaert E, Lasser R. Longacting risperidone: prolonged-release injectable delivery of risperidone using Medisorb® microsphere technology. Schizophr Res 2003; 60(Suppl 1): 314.
11. Samtani MH, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet 2009; 48(9): 585-600.